Chao Deng1, Yufei Xiang1, Tingting Tan1, Zhihui Ren1, Chuqing Cao1, Gan Huang1, Li Wen2, Zhiguang Zhou3. 1. Institute of Metabolism and Endocrinology, The Second Xiangya Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China. 2. Section of Endocrinology, Yale School of Medicine, Yale University, New Haven, CT. 3. Institute of Metabolism and Endocrinology, The Second Xiangya Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China zhouzg@hotmail.com.
Abstract
OBJECTIVE: B lymphocytes play an important role in the immunopathogenesis of autoimmune diabetes. We hypothesized that the altered B-cell subset phenotype is associated with autoimmune diabetes. RESEARCH DESIGN AND METHODS: Patients with type 1 diabetes (T1D) (n = 81), latent autoimmune diabetes in adults (LADA) (n = 82), or type 2 diabetes (T2D) (n = 95) and healthy control subjects (n = 218) with normal glucose tolerance (NGT) were recruited. We determined the percentage of circulating B-lymphocyte subsets, including CD19(+)CD23(-)CD21(+) (marginal zone B [MZB]), CD19(+)CD23(+)CD21(-) (follicular B [FoB]), and CD19(+)CD5(+)CD1d(hi) (interleukin-10-producing regulatory B [B10]) cells by flow cytometry. RESULTS: Patients with T1D or LADA had increased percentages of MZB cells and decreased percentages of FoB cells compared with healthy control subjects with NGT and patients with T2D. Moreover, patients with T1D showed the lowest frequency of B10 cells compared with patients with LADA or T2D, whereas healthy control subjects expressed the highest frequency of B10 cells. Of note, the frequency of MZB cells was negatively associated and the frequency of FoB cells was positively associated with fasting C-peptide (FCP). The frequency of B10 cells was positively correlated with FCP and negatively correlated with hemoglobin A(1c). CONCLUSIONS: The data show that patients with T1D or LADA express an altered frequency of B-cell subsets, which is associated with islet function and glycemia. These findings suggest that B lymphocytes may be involved in loss of self-tolerance and β-cell destruction and could be used as a biomarker and potential target for immunological intervention.
OBJECTIVE: B lymphocytes play an important role in the immunopathogenesis of autoimmune diabetes. We hypothesized that the altered B-cell subset phenotype is associated with autoimmune diabetes. RESEARCH DESIGN AND METHODS: Patients with type 1 diabetes (T1D) (n = 81), latent autoimmune diabetes in adults (LADA) (n = 82), or type 2 diabetes (T2D) (n = 95) and healthy control subjects (n = 218) with normal glucose tolerance (NGT) were recruited. We determined the percentage of circulating B-lymphocyte subsets, including CD19(+)CD23(-)CD21(+) (marginal zone B [MZB]), CD19(+)CD23(+)CD21(-) (follicular B [FoB]), and CD19(+)CD5(+)CD1d(hi) (interleukin-10-producing regulatory B [B10]) cells by flow cytometry. RESULTS:Patients with T1D or LADA had increased percentages of MZB cells and decreased percentages of FoB cells compared with healthy control subjects with NGT and patients with T2D. Moreover, patients with T1D showed the lowest frequency of B10 cells compared with patients with LADA or T2D, whereas healthy control subjects expressed the highest frequency of B10 cells. Of note, the frequency of MZB cells was negatively associated and the frequency of FoB cells was positively associated with fasting C-peptide (FCP). The frequency of B10 cells was positively correlated with FCP and negatively correlated with hemoglobin A(1c). CONCLUSIONS: The data show that patients with T1D or LADA express an altered frequency of B-cell subsets, which is associated with islet function and glycemia. These findings suggest that B lymphocytes may be involved in loss of self-tolerance and β-cell destruction and could be used as a biomarker and potential target for immunological intervention.
Authors: Tania Habib; Andrew Funk; Mary Rieck; Archana Brahmandam; Xuezhi Dai; Anil K Panigrahi; Eline T Luning Prak; Almut Meyer-Bahlburg; Srinath Sanda; Carla Greenbaum; David J Rawlings; Jane H Buckner Journal: J Immunol Date: 2011-11-21 Impact factor: 5.422
Authors: C Akesson; K Uvebrant; C Oderup; K Lynch; R A Harris; A Lernmark; C-D Agardh; C M Cilio Journal: Clin Exp Immunol Date: 2010-04-09 Impact factor: 4.330
Authors: David V Serreze; Harold D Chapman; Marijke Niens; Robert Dunn; Marilyn R Kehry; John P Driver; Michael Haller; Clive Wasserfall; Mark A Atkinson Journal: Diabetes Date: 2011-09-16 Impact factor: 9.461
Authors: Mohammed I Hawa; Charles Thivolet; Didac Mauricio; Irene Alemanno; Elisa Cipponeri; David Collier; Steven Hunter; Raffaella Buzzetti; Alberto de Leiva; Paolo Pozzilli; Richard David G Leslie Journal: Diabetes Care Date: 2008-10-22 Impact factor: 19.112
Authors: Patrick Hanley; Jennifer A Sutter; Noah G Goodman; Yangzhu Du; Debora R Sekiguchi; Wenzhao Meng; Michael R Rickels; Ali Naji; Eline T Luning Prak Journal: Clin Immunol Date: 2017-09-23 Impact factor: 3.969
Authors: Mark A Exley; George C Tsokos; Kingston H G Mills; Dirk Elewaut; Ben Mulhearn Journal: Nat Rev Rheumatol Date: 2016-09-02 Impact factor: 20.543